{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/alopecia-androgenetic-male/","result":{"data":{"firstChapter":{"id":"e3fc5b8b-475e-5a1f-a596-104fbf00064f","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 44ec5568-8f9b-4b4a-b6d9-039398d0c83c --><h1>Alopecia, androgenetic - male: Summary</h1><!-- end field 44ec5568-8f9b-4b4a-b6d9-039398d0c83c -->","htmlStringContent":"<!-- begin item 86d5c694-f449-4c6d-9b6c-6136b91b1b16 --><!-- begin field 6bc6581b-787e-47c8-a1d2-1cda6e595124 --><ul><li>Androgenetic alopecia describes a distinctive pattern of hair loss, which may occur in genetically predisposed men and is thought to be androgen dependent. <ul><li>In men, hair loss usually initially involves the front and sides of the scalp and progresses towards the back of the head.</li></ul></li><li>The underlying pathological process involves pigmented terminal hairs gradually being replaced by smaller, less pigmented hairs similar to vellus hairs.</li><li><div>Male androgenetic alopecia is thought to be a polygenic disorder. It is thought that in genetically predisposed hair follicles there are increased numbers of androgen receptors and/or increased activity of 5-alpha reductase, an enzyme which mediates the effects of androgens on scalp hair.</div></li><li>The prevalence and the severity of androgenetic alopecia is highest in white men, tends to occur less in black men, and later and more slowly in Asian men.<ul><li>By 30 years of age, it affects about a third of white men. This increases to around 80% in men older than 70 years of age. </li></ul></li><li>Complications of androgenetic alopecia include adverse psychosocial effects.</li><li>Hair loss progresses over time in untreated men. The rate of progression is unpredictable and some men eventually lose almost all of the scalp hairs, while others retain a considerable number particularly in the occipital and parietal areas above the ears.</li><li>The diagnosis of androgenetic alopecia is usually made from clinical findings alone.<ul><li>Typically, androgenetic alopecia in men presents with bitemporal recession of the hairline and thinning of the hair of the crown (vertex) and frontal parietal areas.</li></ul></li><li>An underlying cause or alternative diagnosis for the hair loss should be suspected if assessment reveals:<ul><li>Profound shedding or a rapid onset of hair loss which may indicate telogen effluvium.</li><li>Systemic disease, such as a recent severe infection, iron deficiency, or hypothyroidism.</li><li>Exposure to certain drugs, such as antidepressants, anabolic steroids, carbimazole, or chemotherapy.</li><li>Excessive dietary habits or rapid weight loss.</li><li>Inflammation, papules or pustules, scaling, or scarring of the scalp.</li></ul></li><li>Laboratory testing for the diagnosis of androgenetic alopecia is generally unnecessary. <ul><li>Tests for thyroid function, full blood count, and a ferritin level should be considered, particularly if telogen effluvium is suspected, the presentation is atypical, or there are features that suggest hypothyroidism or anaemia.</li></ul></li><li>The natural course of the condition, what the man may expect in terms of continued hair thinning, and the man's wishes regarding treatment and/or aesthetic options should be discussed.</li><li>Options for management include the choice of no treatment, topical minoxidil or oral finasteride — neither treatment option is available on the NHS and both are expensive. <ul><li>Topical minoxidil is available over-the-counter or on a private prescription.</li><li>Oral finasteride 1 mg daily is available on a private prescription only.</li><li>Hair regrowth is not usually noticed for at least 4–6 months with either treatment.</li><li>Stopping treatment will lead to a loss of any benefit within 6–12 months, sometimes with a period of rebound shedding.</li></ul></li><li>Aesthetic options such as hairpieces and wigs, hairstyling, and surgical hair transplantation can be considered.</li><li>Referral to the appropriate specialist should be considered if the man has:<ul><li>An atypical presentation, extensive hair loss, or an uncertain diagnosis.</li><li>A possible underlying condition requiring treatment in secondary care.</li><li>No response to treatments available in primary care.</li><li>Adverse psychosocial effects.</li></ul></li></ul><!-- end field 6bc6581b-787e-47c8-a1d2-1cda6e595124 --><!-- end item 86d5c694-f449-4c6d-9b6c-6136b91b1b16 -->","topic":{"id":"5f58d6a9-7ba5-59ad-b7d6-e461768e2621","topicId":"c4dc3303-ee1d-42aa-8da5-078adb684e06","topicName":"Alopecia, androgenetic - male","slug":"alopecia-androgenetic-male","aliases":[],"chapters":[{"id":"e3fc5b8b-475e-5a1f-a596-104fbf00064f","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"c40b9d81-bd18-5ef2-8284-4c4e6005d65c","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"d860e13e-49f1-54f2-872f-2f3439f27003","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"bbc072f8-3fd9-5a1c-b94c-a0e4fd6edc2f","slug":"changes","fullItemName":"Changes"},{"id":"746928be-2acf-5ae9-9f81-02a942d56a15","slug":"update","fullItemName":"Update"}]},{"id":"3f6cf011-8136-5f24-8cce-31a439cce866","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"5e802365-89ef-5f47-a758-6c880bb456ac","slug":"goals","fullItemName":"Goals"},{"id":"9ed869e3-e3ae-56e1-ae20-0a46d6e20fa2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d90f156b-7429-5580-b4c3-e50d840d1c8a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c879d8ad-590c-56af-9685-9eb9a2e30d54","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9e4f37dc-4cc8-5e88-a803-5ca32ca17da9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5df134be-2105-5321-86a8-71ed6dca8ebb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8a3725c2-b01f-5dd8-a319-33387b40d0ee","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"762358f6-f003-57e8-97ff-1c81299e9364","slug":"definition","fullItemName":"Definition"},{"id":"9ee0c90d-fd96-523f-8f6f-7a26ec56b9c7","slug":"prognosis","fullItemName":"Prognosis"},{"id":"55784b07-7a42-5c0b-9ff3-e9c83216cb1e","slug":"complications","fullItemName":"Complications"},{"id":"7cde82a5-0086-5e04-a669-ec49787685f0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"33fac4d7-a95d-526c-936a-6983e3a12d95","slug":"causes","fullItemName":"Causes"},{"id":"84f86e20-aa91-5e2b-b0b6-bb3cfbf655d6","slug":"risk-factors","fullItemName":"Risk factors"}]},{"id":"4b1bf49e-974e-517b-abd6-59b7ea701502","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"486adc7a-b20b-584e-b20c-1408c8f2dc42","slug":"diagnosis-assessment","fullItemName":"Diagnosis and assessment"},{"id":"afbd97db-7525-51a6-aafe-6e937f1cc3e1","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"4fa73515-d20e-5178-9d6b-eebf5ae2d527","slug":"investigations","fullItemName":"Investigations"}]},{"id":"622bcbbb-d3de-5b15-9b55-ddc4eff327ab","slug":"management","fullItemName":"Management","subChapters":[{"id":"18247780-bdd9-5da4-9d33-1bcf2a883881","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"37e93d68-3a6a-5889-a376-afa236d390aa","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"baab0697-37a1-5edf-88ac-cfb6e2e5656b","slug":"topical-minoxidil-2percent-5percent","fullItemName":"Topical minoxidil 2% and 5%"},{"id":"c42ae7ac-8352-5cac-874c-69c24b99081b","slug":"finasteride","fullItemName":"Finasteride"}]},{"id":"b22c3dba-eb5b-5afa-8f70-43908da7e430","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"444a2a47-2816-5baa-928f-c2bc1b56af85","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"1d1c173f-70b1-5d42-916a-a0bcb5c3557c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"531d7be1-4263-5fd6-a49b-a920a3aaca95","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dede1c7c-59ec-550c-be37-91849715881e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ddffa446-a263-56e2-a985-c07fa5d06760","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3b6f4b5d-c7dd-5142-a6e8-2741d9019ade","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b9ed9ca-1edc-5d61-938a-a6abc5daa77a","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"5f58d6a9-7ba5-59ad-b7d6-e461768e2621","topicId":"c4dc3303-ee1d-42aa-8da5-078adb684e06","topicName":"Alopecia, androgenetic - male","slug":"alopecia-androgenetic-male","aliases":[],"topicSummary":"Androgenetic alopeciadescribes a distinctive pattern of hair loss, which may occur in genetically predisposed men","lastRevised":"Last revised in July 2018","nextPlannedReviewBy":"2021-07-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2021-06","nextPlannedReviewByDisplay":"June 2021","specialities":[{"id":"50071c38-ab10-5ab8-ac70-6bd19a96c24e","name":"Skin and nail","slug":"skin-nail"},{"id":"34b90622-9d68-500d-98a2-3c80efbae845","name":"Men's health","slug":"mens-health"}],"chapters":[{"id":"e3fc5b8b-475e-5a1f-a596-104fbf00064f","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"c40b9d81-bd18-5ef2-8284-4c4e6005d65c","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"d860e13e-49f1-54f2-872f-2f3439f27003","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"bbc072f8-3fd9-5a1c-b94c-a0e4fd6edc2f","slug":"changes","fullItemName":"Changes"},{"id":"746928be-2acf-5ae9-9f81-02a942d56a15","slug":"update","fullItemName":"Update"}]},{"id":"3f6cf011-8136-5f24-8cce-31a439cce866","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"5e802365-89ef-5f47-a758-6c880bb456ac","slug":"goals","fullItemName":"Goals"},{"id":"9ed869e3-e3ae-56e1-ae20-0a46d6e20fa2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d90f156b-7429-5580-b4c3-e50d840d1c8a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c879d8ad-590c-56af-9685-9eb9a2e30d54","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9e4f37dc-4cc8-5e88-a803-5ca32ca17da9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5df134be-2105-5321-86a8-71ed6dca8ebb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8a3725c2-b01f-5dd8-a319-33387b40d0ee","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"762358f6-f003-57e8-97ff-1c81299e9364","slug":"definition","fullItemName":"Definition"},{"id":"9ee0c90d-fd96-523f-8f6f-7a26ec56b9c7","slug":"prognosis","fullItemName":"Prognosis"},{"id":"55784b07-7a42-5c0b-9ff3-e9c83216cb1e","slug":"complications","fullItemName":"Complications"},{"id":"7cde82a5-0086-5e04-a669-ec49787685f0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"33fac4d7-a95d-526c-936a-6983e3a12d95","slug":"causes","fullItemName":"Causes"},{"id":"84f86e20-aa91-5e2b-b0b6-bb3cfbf655d6","slug":"risk-factors","fullItemName":"Risk factors"}]},{"id":"4b1bf49e-974e-517b-abd6-59b7ea701502","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"486adc7a-b20b-584e-b20c-1408c8f2dc42","slug":"diagnosis-assessment","fullItemName":"Diagnosis and assessment"},{"id":"afbd97db-7525-51a6-aafe-6e937f1cc3e1","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"4fa73515-d20e-5178-9d6b-eebf5ae2d527","slug":"investigations","fullItemName":"Investigations"}]},{"id":"622bcbbb-d3de-5b15-9b55-ddc4eff327ab","slug":"management","fullItemName":"Management","subChapters":[{"id":"18247780-bdd9-5da4-9d33-1bcf2a883881","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"37e93d68-3a6a-5889-a376-afa236d390aa","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"baab0697-37a1-5edf-88ac-cfb6e2e5656b","slug":"topical-minoxidil-2percent-5percent","fullItemName":"Topical minoxidil 2% and 5%"},{"id":"c42ae7ac-8352-5cac-874c-69c24b99081b","slug":"finasteride","fullItemName":"Finasteride"}]},{"id":"b22c3dba-eb5b-5afa-8f70-43908da7e430","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"444a2a47-2816-5baa-928f-c2bc1b56af85","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"1d1c173f-70b1-5d42-916a-a0bcb5c3557c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"531d7be1-4263-5fd6-a49b-a920a3aaca95","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dede1c7c-59ec-550c-be37-91849715881e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ddffa446-a263-56e2-a985-c07fa5d06760","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3b6f4b5d-c7dd-5142-a6e8-2741d9019ade","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b9ed9ca-1edc-5d61-938a-a6abc5daa77a","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"5f58d6a9-7ba5-59ad-b7d6-e461768e2621"}},"staticQueryHashes":["3666801979"]}